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ABSTRACT
MicroRNAs (miRNAs) play a critical role in development and progression of 
cancers. Deregulation of MicroRNA-9 (miR-9) has been documented in many types 
of cancers but their role in the development of esophageal squamous cell carcinoma 
(ESCC) has not been studied. This study aimed to investigate the effect of miR-9 in 
esophageal cancer metastasis. The up-regulation of miR-9 was frequently detected 
in primary ESCC tumor tissue, which was significantly associated with clinical 
progression (P = 0.022), lymph node metastasis (P = 0.007) and poor overall survival 
(P < 0.001). Functional study demonstrated that miR-9 promoted cell migration and 
tumor metastasis, which were effectively inhibited when expression of miR-9 was 
silenced. Moreover, we demonstrated that miR-9 interacted with the 3’-untranslated 
region of E-cadherin and down-regulated its expression, which induced β-catenin 
nuclear translocation and subsequently up-regulated c-myc and CD44 expression. 
In addition, miR-9 induced epithelial-mesenchymal transition (EMT) in ESCC, a key 
event in tumor metastasis. Taken together, our study demonstrates that miR-9 plays 
an important role in ESCC metastasis by activating β-catenin pathway and inducing 
EMT via targeting E-cadherin. Our study also suggests miR-9 can be served as a 
new independent prognostic marker and/or as a novel potential therapeutic target  
for ESCC.
INTRODUCTION
Esophageal cancer is one of the most common 
solid malignancies in the world and ranks as the sixth-
leading cause of cancer-related mortality [1]. Esophageal 
squamous cell carcinoma (ESCC) is the predominant 
histologic type in East Asia, especially in the high-risk 
areas in northern China [2, 3]. Despite the great advances 
achieved in diagnosis and multimodality therapies 
recently, the prognosis of ESCC is still poor with a dismal 
5-year survival rate of 20–30% [4]. The high probability 
of metastasis and recurrence is still the major reason of 
grim prognosis, yet the precise molecular mechanism of 
metastatic dissemination is still not completely clear [3]. 
Therefore, understanding the factors involved in ESCC 
metastasis is required for the identification of new 
prognostic biomarkers and therapeutic targets.
In the last few years, growing body of evidences 
indicate that microRNAs (miRNAs) are involved 
in multiple cellular processes as posttranscriptional 
regulators and particularly in cancer development and 
progression [5, 6]. miRNAs are a diverse class of 20–24 
nucleotide that plays important roles in gene regulation 
by pairing to the 3′-untranslated region (3′-UTR) of target 
mRNAs to direct their posttranscriptional repression [7]. 
Deregulation of miRNAs has been reported to play roles 
Oncotarget11670www.impactjournals.com/oncotarget
in ESCC metastasis by acting as activators or inhibitors 
[8–10]. In our recent study, microarray strategy was 
applied to identify differentially expressed miRNAs in 
ESCC cells by comparing miRNA profiles between tumor 
and paired non-tumor tissues [11]. MiR-9 was investigated 
in this study because its deregulation has been reported 
in several types of cancers, including breast cancer [12], 
colorectal cancer [13] and melanoma [14]. However, the 
role of miR-9 in the development and progress of ESCC 
remains unclear. In the present study, overexpression of 
miR-9 was frequently detected in primary ESCC cases, 
which was associated with clinical progression, lymph 
node metastasis and poor overall survival. Functional 
study found that miR-9 increased cell motility in vitro and 
tumor metastasis in vivo. Although E-cadherin has been 
documented as a target of miR-9 in breast cancer [12], 
we further demonstrated that miR-9 directly targeted the 
3′-UTR of E-Cadherin and activated the β-catenin 
signaling pathway in ESCC.
RESULTS
Up-regulation of miR-9 is frequently  
detected in ESCC
To evaluate expression situation of miR-9 in clinical 
ESCC specimens, quantitative real-time PCR (qRT-PCR) 
was used to compare expression levels of miR-9 between 
tumor and corresponding non-tumor esophageal mucosa in 
67 ESCCs. Up-regulation of miR-9 was detected in 35/67 
(52.24%) of ESCC tumors, compared with corresponding 
nontumorous tissues (defined as >2-fold increase). The 
average miR-9 expression was significantly higher in tumor 
tissues than in their normal counterparts (P = 0.0016) 
(Figure 1A). Expression level of miR-9 in 9 human ESCC 
cell lines was also detected by qRT-PCR and the result 
showed that up-regulation of miR-9 could be detected in 
8/9 cell lines (except EC109) compared with a pool of 
5 nontumorous tissues as a normal control (Figure 1B).
Up-regulation of miR-9 is associated with  
ESCC metastasis and poor prognosis
To investigate the clinical significance of miR-9  
up-regulation in ESCC, expression of miR-9 was evaluated 
by microRNA in situ hybridization (MISH) in a tissue 
microarray containing 300 pairs of primary ESCCs and 
their paired non-tumor samples. Informative results 
were observed in 243 pairs of ESCC cases, while non-
informative cases included lost samples and samples 
with limited number of cells. The overexpression 
of miR-9, defined as its fluorescent signals in tumor 
tissue obviously more and stronger than that in the 
corresponding non-tumor tissue, was detected in 82/243 
(33.74%) of informative ESCC tissues (Figure 1C). The 
clinical association analysis found that overexpression 
of miR-9 was significantly associated with advanced 
clinical stage (P = 0.022) and lymph node metastasis 
(P = 0.007, Table 1). Kaplan-Meier analysis indicated 
that overexpression of miR-9 was significantly associated 
with poorer overall survival (log-rank test, P < 0.001, 
Figure 1D). Further, multivariate Cox regression analysis 
revealed that overexpression of miR-9 is an independent 
prognostic factor for poor survival of patients with ESCC 
(P = 0.009, Table 2).
miR-9 promotes cell migration  
and tumor metastasis
To investigate the oncogenic function of miR-9, 
miR-9 was cloned into a lentiviral vector and stably 
transfected into ESCC cell lines HKESC1 and KYSE410 
(Figure 2A). Empty vector-transfected cells were used 
as controls. Tumorigenic effect of miR-9 was studied by 
XTT cell growth assay, foci formation assay and tumor 
formation in nude mice. Unexpectedly, no significant 
difference was detected by XTT assay between miR-9 
transfected cells and control cells (data not shown). Foci 
formation and tumor formation in nude mice showed that 
miR-9 could increase number of foci formed and promote 
tumor growth in tested mice in KYSE410 cells, but not in 
HKESC1 cells (Figure 2B and 2C). Since overexpression 
of miR-9 has been significantly associated with ESCC 
metastasis, its role in cell migration and invasion was 
then investigated by both in vitro and in vivo assays. Cell 
migration assay showed that miR-9 could significantly 
increase cell motility in HKESC1 and KYSE410 cells 
compared with the empty vector-transfected cells 
(P < 0.01, Figure 3A). When endogenous miR-9 was 
silenced by a siRNA against miR-9 in KYSE30 and 
KYSE510 cells (Figure 3B), the number of migrated cells 
decreased significantly compared with scramble siRNA-
transfected control cells (P < 0.01, Figure 3C).
To further validate the effect of miR-9 on tumor 
metastasis, in vivo metastasis assay was performed in 
nude mice. miR-9 expressing HKESC1 (HK-miR-9) and 
KYSE410 (410-miR-9) cells were injected into nude 
mice via tail vein, respectively. Empty vector trasfected 
cells were used as controls (HK-Vec and 410-Vec). Eight 
weeks later, tested mice were sacrificed and the metastatic 
modules formed on the lungs and livers were counted. 
No visible metastatic nodule was observed in livers of 
mice except one HK-miR-9 mouse (data not shown). 
Pulmonary metastatic nodules induced by HK-miR-9 cells 
and HK-Vec cells were detected in 7/7 and 5/7 of tested 
mice, respectively. As shown in Figure 3D, the number 
of pulmonary metastatic nodules induced by HK-miR-9 
cells was significantly higher than that induced by control 
cells (P < 0.001, independent student’s t test). Histological 
study with H&E stained paraffin block sections confirmed 
that the pulmonary nodules were metastatic cancers 
(Figure 3E). IHC staining with anti-cytokeratin antibody 
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was performed to validate that the cells originated from 
injected tumor cells (Figure 3E). MISH demonstrated that 
miR-9 was overexpressed in metastatic nodule induced 
by miR-9 overexpressed cells compared with control 
cells (Figure 3E). The pulmonary metastatic nodules 
induced by 410-miR-9 cells could be only observed in one 
mouse whereas no visible tumor nodule was observed in 
410-Vec mice (Figure 3F). Histological and MISH studies 
confirmed the metastatic nodule was cancer with miR-9 
overexpression (Figure 3G).
Figure 1: miR-9 was frequently up-regulated in primary ESCC cases and cell lines. (A) qRT-PCR shows that miR-9 was 
frequently up-regulated in 67 primary ESCC tissues compared with their adjacent non-tumor tissues. (P = 0.0016, independent t test). 
Expression of miR-9 was shown in log10 scale and normalized to U6. (B) Up-regulation of miR-9 was detected in all tested ESCC cell lines 
except EC109 compared with pool of non-tumor tissues (N). U6 was set as an endogenous control. *P < 0.05; **P < 0.001. (C) Representative, 
of miR-9 expression (green signals) in a pair of ESCC tumor tissue and corresponding non-tumor tissue detected by MISH. Nuclei were 
conterstained by DAPI (blue color). Original magnification, 40 × objective. (D) Kaplan-Meier analysis indicates up-regulation of miR-9 
was significantly associated with poorer overall survival rates of ESCC patients (P < 0.001).
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Table 1: Clinicopathological correlation of miR-9 expression in ESCC
Feature
miR-9 expression level
All Normal Upregulated P
Age
0.069 ≤60 years 139 98(70.5) 41(29.5)
 >60 years 104 63(60.6) 41(39.4)
Differentiation
0.093
 Well 60 33(55.0) 27(45.0)
 Moderate 156 108(69.2) 48(30.8)
 Poor 27 20(74.1) 7(25.9)
Tumer invasion
0.705
 T1 18 12(66.7) 6(33.3)
 T2 18 10(55.6) 8(44.4)
 T3 45 32(71.1) 13(28.9)
 T4 162 107(66.0) 55(34.0)
Lymph node 
metastasis
0.007* N0 138 101(73.2) 37(26.8)
 N1 105 60(57.1) 45(42.9)
Clinical stage
0.022* Stage I-II 161 115(71.4) 46(28.6)
 Stage III-IV 82 46(56.1) 36(43.9)
*Significant difference
Table 2: Cox proportional hazard regression analyses for overall survival
Clinicopathological 
Features
Univariate Analysis Multivariate Analysis
HR(95%Cl) P HR ( 95%Cl ) P
miR-9 UPregulation 1.913(1.391–2.632) <0.001* 1.543 (1.112–2.140) 0.009*
Gender 0.785(0.568–1.085) 0.142
Age 1.216(0.886–1.669) 0.225
Differentiation 1.574(1.192–2.079) <0.001* 1.465(1.114–1.928) 0.006*
Tumor invasion 1.481(1.197–1.831) <0.001* 1.267(1.012–1.586) 0.039*
Clinical stage 2.483(1.802–3.420) <0.001* 1.545 (0.799–2.990) 0.196
LN metastasis 2.138(1.556–2.938) <0.001* 1.218 (0.654–2.268) 0.534
CI = confidence interval; HR = hazard ratio;
*Statistical significance (p < 0.05) is shown in bold.
E-cadherin is a putative target  
of miR-9 in ESCC
By searching the targets of miR-9 with TargetScan 
and miRanda, one potential target E-cadherin was selected 
for further study because it has been associated with tumor 
metastasis [15]. 3′-UTR of E-cadherin mRNA contains 
one complementary site for miR-9. To examine whether 
E-cadherin is regulated by miR-9 in ESCC, we tested the 
expression of E-cadherin in miR-9 overexpressed cell 
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lines HKESC1 and KYSE410. qRT-PCR and western 
blotting results showed that expression of E-cadherin was 
significantly reduced in HKESC1 and KYSE410 when 
miR-9 was stably transfected into these cells compared 
with empty vector-transfected control cells (P < 0.01, 
Figure 4A). When miR-9 was silenced in KYSE30 and 
KYSE510 cells, expression of E-cadherin was increased 
significantly (P < 0.01, Figure 4B).
A luciferase reporter assay was then performed to 
verify whether E-cadherin is the direct target of miR-9. The 
potential miR-9 binding sequence in the 3′-UTR region of 
E-cadherin was cloned into a luciferase reporter vector and 
transiently transfected into the miR-9 overexpressed cells 
and vector control cells. Decreased luciferase activity in 
miR-9 overexpressed cells was observed compared with 
the control cell (Figure 4C), indicating that E-cadherin 
was a downstream target of miR-9.
miR-9 level is negatively correlated with 
expression of E-cadherin in ESCC
To investigate the correlation between expressions 
of miR-9 and E-cadherin in clinical samples, IHC 
was performed using a TMA containing 300 pairs of 
primary ESCCs. Informative results were observed 
in 237 pairs (both tumor and non-tumor tissues) of 
ESCCs. Non-informative cases were mainly caused by 
tissue loss in either tumor or paired non-tumor tissues. 
E-cadherin staining was calculated by adding the scores 
for the percentage and intensity of positive staining of 
E-cadherin. Since the staining index of E-cadherin in non-
tumor samples was ≥5, down-regulation of E-cadherin 
was defined as staining index <5. Down-regulation 
of E-cadherin was detected in 103/237 (43.5%) of 
informative ESCC tissues compared with their paired 
non-tumor tissues (Figure 4D). Moreover, the correlation 
between miR-9 and E-cadherin was analyzed by Pearson 
χ2 test in 216 cases with both miR-9 and E-cadherin 
information, a negative correlation was detected between 
miR-9 and E-cadherin (P = 0.02, Supplementary Table 1).
miR-9 promotes tumor metastasis via  
nuclear translocation of β-catenin
E-cadherin/β-catenin complex is known for 
connecting the actin cytoskeleton to the adherens junctions 
[16]. When the cytoplasmic E-cadherin decreased, β-catenin 
is released from the complex. Stabilized “free” β-catenin 
goes to the nucleus, binds T-cell factor/lymphoid enhancer 
factor (TCF/Lef) and activates transcription of target 
genes such as c-myc, cyclin D1, CD44 and VEGF, which 
are responsible for cell proliferation and metastasis [17]. 
Figure 2: Functional study of miR-9. (A) Relative expression of miR-9 was detected by qRT-PCR in miR-9-transfected (R9) 
HKESC1 and KYSE410 cells compared with empty vector-transfected cells (V). **P < 0.001. (B) Foci formation assay was performed to 
compare frequency of foci formation between miR-9- and empty vector-transfected cells. Results are expressed as mean ±S.E.M. of three 
independent experiments. *P < 0.05. (C) Representative images of xenografts and summary of tumor weight in tumor formation in nude 
mice. miR-9- and empty vector-transfected cells were inoculated subcutaneously to the flanks of nude mice. Xenografts were isolated and 
weighted after 4 weeks.
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Figure 3: miR-9 promotes cell migration and tumor metastasis. (A) Representative images and summary of cell migration assay. 
Compared with empty vector-transfected cells, miR-9-transfected cells could promote cell migration in HKESC1 and KYSE410 cells. The 
results are expressed as mean ± S.E.M. of three independent experiments. **P < 0.01. (B) Down-regulation of miR-9 was detected by 
qRT-PCR when miR-9 was silenced by a siRNA in KYSE30 and KYSE510 cells. Cells treated with scramble siRNA were used as control 
cells. Results are expressed as mean ± S.E.M. of three independent experiments. **P < 0.01. (C) Representative images and summary 
of migrated cells between siRNA-miR-9 and scramble siRNA treated KYSE30 and KYSE510 cells. The results are expressed as mean 
± S.E.M. of three independent experiments. **P < 0.01. (D) miR-9 could promote ESCC metastasis in vivo. Representative images of 
lungs derived from mice injected with HK-miR-9 and control cells (upper). Visible tumor nodules were counted and summarized (bottom). 
(E) H&E staining (upper) and IHC staining of CK (middle) was performed on pulmonary sections derived from mice. Original magnification: 
20 × objective. Expression of miR-9 (green signals) was detected by MISH in pulmonary sections (bottom). Original magnification: 
40 × objective. (F) Representative image of lung derived from mice injected with 410-miR-9 and control cells. (G) H&E staining (upper) 
was performed on pulmonary sections derived from mice injected with 410-miR-9 and control cells. Original magnification: 40 × objective. 
Expression of miR-9 was detected by MISH in pulmonary sections (bottom). Original magnification: 20 × objective.
To explore the molecular mechanism of miR-9/E-cadherin 
in promoting metastasis, subcellular localization of 
β-catenin was detected by immunofluorescence (IF) 
analysis. IF result showed that β-catenin translocation 
from the cell membrane to nucleus was observed in 
both miR-9-transfected HKESC1 and KYSE410 cells, 
whereas β-catenin was mainly located on the membrane 
in the empty vector-transfected cells (Figure 5A). To 
determine whether the nuclear translocation of β-catenin 
can upregulate its downstream target genes, western 
blot analysis was used to test expressions of c-myc, 
cyclin D1, CD44 and VEGF. Increased expressions of 
c-myc, CD44 and VEGF were detected in HK-miR-9 and 
410-miR-9 cells compared with their control cells 
(Figure 5B). No significant change was observed on cyclin 
D1 protein level. When miR-9 was knocked down in 
KYSE30 and KYSE510 cells, the protein levels of c-myc, 
CD44 and VEGF were decreased (Figure 5C).
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miR-9 induces epithelial-mesenchymal  
transition in ESCC
As epithelial-mesenchymal transition (EMT) is 
one of the key events involved in invasion and metastasis 
of tumor cells, several epithelial markers (β-catenin 
and α1-catenin) and mesenchymal markers (Vimentin 
and Fibronectin) were tested by Western blot analysis. 
The results found that down-regulations of epithelial 
markers were not obvious except decrease of 
α1-catenin in HK-miR-9 cells (Figure 5D). Upregulation 
of Vimentin and Fibronectin could be detected in both 
HK-miR-9 and 410-miR-9 cells (Figure 5D). In miR-9 
silenced KYSE30 and KYSE510 cells, mesenchymal 
markers were down-regulated except Vimentin in 
KYSE30 cells (Figure 5E). These data suggest that 
miR-9 could induce partial EMT that promoted cancer 
cell invasion and metastasis.
DISCUSSION
Previous studies have reported that miRNAs, such as 
oncomiRs or anti-oncomiRs, play important roles in cancer 
development and progression by acting as activators 
or inhibitors [18]. More recently, several specialized 
miRNAs termed metastamirs have been implicated in 
the regulation of tumor metastasis [19]. Metastamirs 
always play important roles in various steps of metastasis 
rather than tumorigenesis.[12, 19, 20] Characterization of 
metastamirs and their targets involved in the progression 
of ESCC may lead to the identification of novel prognostic 
markers and therapeutic targets. miR-9, a highly conserved 
microRNA, was reported to be expressed predominantly 
in the central nervous system of the developing embryo 
exhibiting a prodifferentiation function [21]. In addition 
to its involvement in neurogenesis, miR-9 was first 
found to be up-regulated in primary brain tumors [22]. 
Figure 4: miR-9 down-regulates E-cadherin in ESCC cells. (A) qRT-PCR and Western blotting results showed that miR-9 could 
effectively down-regulate E-cadherin expression in HK-miR-9 and 410-miR-9 cells compared with control cells. qRT-PCR results were 
expressed as mean ± S.E.M. of three independent experiments. **P < 0.001. GAPDH was set as an internal control in Western blot analysis. 
(B) Expressions of E-cadherin in both mRNA and protein levels were increased when miR-9 was silenced in KYSE30 and KYSE510 cells 
by a siRNA against miR-9, compared with scramble siRNA-treated cells. C, control scramble siRNA; si, siRNA against miR-9. **P < 0.01. 
(C) Luciferase assay was performed to confirm that miR-9 could target E-cadherin. miR-9 overexpressed cells and control cells were 
co-transfected with pMIR-REPORT-CDH1(3′-UTR)/empty vector with pRL-TK, and relative luciferase activity was detected. *P < 0.05. 
(D) Representative pictures of E-cadherin staining (by IHC) and miR-9 (by MISH) in a pair of ESCC tumor tissue and corresponding 
non-tumor tissue. Results showed that E-cadherin was down-regulated in miR-9 overexpressed tumor tissue. Original magnification: 
20 × objective.
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Figure 5: miR-9 activates β-catenin pathway and induces EMT. (A) IF showed that nuclear translocation of β-catenin (red) 
happened in miR-9-transfected cells while β-catenin located mainly on the membrane in empty vector-transfected cells. Nuclei were 
counterstained with DAPI. Original magnification: 40 × objective. (B-E) Western blot analysis was used to compare protein expression 
levels between miR-9- and empty vector-transfected cells (B and D), or between cells treated with siRNA against miR-9 and scramble 
siRNA (C and E). GAPDH was set as internal control.
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Up-regulation of miR-9 has been also reported in breast 
cancer [12], colorectal cancer [13] and melanoma [14]. 
Interestingly, down-regulation of miR-9 has been reported 
in gastric [23] and ovarian cancers [24], suggesting the 
diversity role of miR-9 in different cancers.
Here we report that miR-9 was frequently 
up-regulated in primary ESCC tumors, which was 
significantly associated with advanced clinical stage 
(P = 0.022), lymph node metastasis (P = 0.007) and poor 
survival rate (P < 0.001) of ESCC. Moreover, multivariate 
Cox regression analysis revealed that up-regulation 
of miR-9 is an independent prognostic factor for poor 
survival of patients with ESCC. Functional study found 
that miR-9 could increase cell migration and metastasis, 
implying that miR-9 is a metastamiR in ESCC, and it 
could be used as a prognostic biomarker in ESCC.
As reported by many studies, informatics analysis 
indicated that E-cadherin might be the downstream 
target of miR-9 [12, 25] . In the present study, E-cadherin 
was down-regulated in miR-9 overexpressed cells and 
up-regulated when endogenous miR-9 was silenced. 
Luciferase assay also confirmed that miR-9 could target 
E-cadherin directly. E-cadherin is a crucial protein 
mediated cell-cell adhesion to hold the epithelial cells 
tight together. Loss of E-cadherin decreases the cellular 
adhesion, resulting in an increase in cellular motility [26]. 
It has been reported that down-regulation of E-cadherin in 
esophageal carcinoma was associated with an increased 
invasive and metastatic potential [15]. Moreover, 
E-cadherin can sequester β-catenin as a complex to 
connect the actin cytoskeleton to the adherent junctions 
[26]. Upon loss of E-cadherin expression, β-catenin was 
released from the complex. Stabilized “free” β-catenin 
goes to the nucleus and modulates b-catenin/Tcf-mediated 
gene expression to promote cell invasion and metastasis 
[27]. It was also reported that loss of E-cadherin activates 
EGFR-MEK/ERK signaling and promotes invasion in non-
small cell lung cancer [28]. Recently, Ma et al. reported 
that miR-9 could target E-cadherin and allow liberation 
of β-catenin, which then activates the VEGF to promote 
metastasis in breast cancer [12]. Our results confirmed 
miR-9 to be involved in regulation of cell metastasis by 
targeting E-cadherin in ESCC. In the ESCC primary tumor 
tissues, miR-9 is negatively correlated with the expression 
of E-cadherin (R = -0.163, P < 0.05). Although miR-9 
could not cause significant change on β-catenin protein 
level, the nuclear translocation of β-catenin was observed 
in miR-9 overexpressed cells. Western blotting analysis 
demonstrated that the downstream targets of β-catenin, 
including VEGF, c-myc and CD44 were up-regulated in 
miR-9 overexpressed cells, suggesting that these genes 
may participate in the tumor metastasis in ESCC.
Since epithelial-mesenchymal transition is one 
of the key events involved in tumor invasion and 
metastasis [27], the effect of miR-9 on EMT was also 
investigated in the study. As we mentioned earlier, no 
significant change on β-catenin protein level was observed. 
α1-catenin decreased in HK-miR-9 cells and increased in 
miR-9 silenced KYSE30 cells. Changes of 2 mesenchymal 
markers (Vimentin and Fibronectin) were also detected in 
miR-9 overexpressed and silenced cells, suggesting that the 
metastatic effect of miR-9 was via inducing EMT in ESCC. 
In summary, miR-9 was frequently overexpressed in ESCC 
specimens and played a crucial role in ESCC metastasis 
through targeting E-cadherin, promoting β-catenin nuclear 
translocation and subsequently inducing EMT.
MATERIALS AND METHODS
Cell lines and primary tumor tissues
Six ESCC cell lines (KYSE30, KYSE140, KYSE180, 
KYSE410, KYSE510, and KYSE520) were obtained from 
DSMZ (Braunschweig, Germany), the German Resource 
Centre for Biological Material [29]. Three Chinese ESCC 
cell lines (EC18, EC109, and HKESC1) were kindly 
provided by our fellows at the University of Hong Kong 
(Professors G. Srivastava and G.S. Tsao) [30]. Sixty seven 
pairs of primary ESCCs and corresponding nontumorous 
tissues were collected directly after surgical resection 
at Linzhou Cancer Hospital (Henan, China). A total of 
300 formalin-fixed and paraffin-embedded ESCCs and 
their adjacent nontumorous tissue samples were also kindly 
provided by Linzhou Cancer Hospital. All patients recruited 
in the study did not receive preoperative treatment. 
Clinical samples used in this study were approved by the 
Committees for Ethical Review of Research at Zhengzhou 
University (Zhengzhou, China) and Sun Yat-Sen University 
Cancer Center (Guangzhou, China).
RNA isolation and quantitative real-time PCR
Total RNA was extracted with TRIzol (Invitrogen, 
Calsbad, CA) according to the manufacturer’s instructions. 
Reverse transcription was performed using the 
PrimeScriptRT reagent Kit (Promega, Madison, WI). Real-
time PCR was carried out using SYBR Green SuperMix 
(Roche, Basel, Switzerland) and ABI7900HT Fast Real-
Time PCR system (Applied Biosystems, Foster City, CA). 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 
U6 was used as internal control. The primers of miR-9 
and U6 were purchased from HAPK Biotechnonology 
(Shenzhen, China). Other primer sequences used in the 
study were listed in supporting data.
Tissue microarray (TMA) and 
immunohistochemical staining (IHC)
Tissue microarray containing 300 pairs of primary 
ESCC cases (tumor and corresponding non-tumor tissues) 
was constructed as described previously [31]. None of 
the patients in the study has received follow-up radiation 
or chemotherapy. IHC was performed using a standard 
streptavidin-biotin-peroxidase complex method. In brief, 
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a TMA section was deparaffinized and rehydrated. 
Endogenous peroxidase activity was blocked with 0.3% 
hydrogen peroxide for 15 minutes. For antigen retrieval, 
the TMA slide was microwave-treated in 10 mM citrate 
buffer (pH 6.0) for 10 minutes. The slide was then 
incubated with anti-E-cadherin monoclonal antibody (Cell 
Signalling Technology, Danvers, MA). The nucleus was 
counterstained using Meyer’s hematoxylin. E-cadherin 
immunoreactivity was calculated by adding the scores 
for the percentage of E-cadherin -positive cells (<5%, 0; 
5%–25%, 1; 25%–50%, 2; 50%–75%, 3; >75%, 4) and 
the intensity of E-cadherin-positive staining (negative, 0; 
weak, 1; moderate, 2; or strong, 3). Informative results 
were observed in 237 pairs of ESCC cases, while 
non-informative samples included lost samples and 
inappropriate staining.
microRNA in situ hybridization (MISH)
An oligonucleotide probe 
(5′-TCATACAGCTAGATAACCAAAGA-3′) 
complementary to hsa-miR-9-5p was purchased 
from the Exonbio Lab (Guangzhou, China). This 
oligonucleotide contains three 2’-fluoro-modified RNA 
residues (2’-F RNA) at the 4th, 10th and 20th bases, 
which can increase melting temperature and result in 
enhanced hybridization stability. Both 5′ and 3′ ends 
were labeled by digoxin (DIG). A scramble probe 
5′-TCTTACACCTAGATAAGCAAAGA-3′ was used as 
a negative control. MISH was performed as described 
previously [32]. Informative results were observed in 
243 pairs of ESCCs. Non-informative cases included lost 
samples and samples with limited number of cells.
Establishment of miR-9 overexpression  
ESCC cell lines
Lentiviral construct containing pre-miR-9 
(GeneCopoeia, China) was packaged using the ViraPower 
Mix (Invitrogen, Carlsbad, CA) in 293FT cells. 
pre-miR-9-expressing lentivirus was used to stably 
transfect ESCC cells (KYSE410 and HKESC1) to establish 
miR-9-overexpressing cells. Empty vector-transfected 
cells were established as controls. A siRNA against 
miR-9 (Genepharma, China) was transfected into 
KYSE30 and KYSE510 cells using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions. The cells transfected with 
scrambled inhibitor (NC) (Genepharma, China) were used 
as negative controls.
Cell growth assay, foci formation assay  
and in vivo tumor formation assay
For cell growth assay, 1 × 103 cells were plated in 
96-well plates and the cell growth rate was assayed 
by CCK-8 kit (Dojindo, Japan) according to the 
manufacturer’s instruction. For foci formation assay, 
1 × 103 cells were plated in 6-well plates, After 2 weeks 
culture, colonies consisted of >50 cells were counted 
with 1% crystal violet staining. Triplicate independent 
experiments were performed.
Animal experiments were performed in compliance 
with the guidelines for the Welfare of Experimental 
Animals in Sun Yat-sen University Cancer Center. For 
in-vivo study, HK-miR-9 (2 × 106), 410-miR-9 (3 × 106) 
and empty vector transfected control cells were 
subcutaneously injected into the dorsal flanks of nude 
mice, respectively (4 for HKESC1 group and 5 for 
KYSE410 group). After 4 weeks, tumor formation in nude 
mice was examined by measuring tumor weight.
Cell motility assay
Migration assay was performed with migration 
chamber (BD Biosciences, Flanklin Lakes, NJ) following 
the manufacturer’s instructions. Cells located on the lower 
side of the chamber were fixed, stained, and counted under 
a microscope. Triplicate independent experiments were 
performed.
In vivo metastasis assay
For the in vivo metastasis assays, 7 × 105 cells were 
injected intravenously through the tail vein into 4- to 
5-week-old nude mouse (7 for HKESC1 group and 6 for 
KYSE410 group), respectively. The mice were sacrificed 
8 weeks later and the intrahepatic and pulmonary 
metastatic nodules were carefully examined and counted. 
The livers and lungs were fixed for further study. The 
tissue blocks were cut into 5 μm sections and stained with 
haematoxylin-eosin.
Antibodies and Western blotting
Quantified protein lysates were resolved on 
SDS-PAGE gel, transferred onto PVDF membrane 
(Millipore, Billerica, MA), and immunoblotted with 
anti-human antibodies E-cadherin, β-catenin, Vimentin, 
α1-catenin, cyclin D1, c-myc (Cell Signalling 
Technology, Danvers, MA), GAPDH and CD44 (Santa 
Cruz, CA), VEGF (BD Biosciences, Franklin Lakes, NJ), 
and cytokeratin (Maixin, China). Blots were visualized 
with enhanced chemiluminescence (Amersham 
Biosciences, Piscataway, NJ).
Luciferase assay
An 819-bp fragment of CDH1 3′-UTR containing 
the putative binding site of miR-9 was amplified by PCR 
(Supporting data) and cloned into pMIR-REPORT vector 
(Ambion, Carlsbad, CA). The miR-9 overexpressed 
cells and the vector control cells were transfected with 
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the reporter constructs containing the target binding 
sequence of CDH1, the pMIR-REPORT vector was 
used as control. Renilla luciferase vector (pRL-TK) was 
cotransfected into KYSE410 and HKESC1 cells as a 
normalizing transfection control, Dual luciferase signals 
were measured 48 hours later by the Dual-luciferase assay 
kit (Promega, Madison, WI).
Immunofluorescence (IF)
Immunofluorescence analysis was performed 
as described previously [33]. Briefly, cells were fixed 
and incubated with the primary antibody β-catenin 
(Immunofluorescence Preferred; Cell Signaling 
Technology, Danvers, MA) overnight at 4°C. After 
washing with PBS, cells were then incubated with 
fluorescence-conjugated secondary antibody (Invitrogen, 
Calsbad, CA). Images were captured after stained with 
Anti-fade DAPI solution.
Statistical analysis
SPSS standard V.16.0 (SPSS, Inc., IL) was used 
for Statistical analysis, Student’s t tests was used to 
analysis the significance of difference. Survival analysis 
was performed using Kaplan-Meier plots and log-rank 
tests. The correlation between miR-9 expression and 
clinicopathological characteristics was analyzed by 
Pearson χ2 test. Univariable and multivariable Cox 
proportional hazard regression model was used to 
assess the survival hazard. Differences were considered 
significant when P < 0.05.
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